BF Biosciences

What BF Biosciences does

BF Biosciences Limited is a Pakistani biopharmaceutical company operating as a joint venture between Ferozsons Laboratories Limited (Pakistan) and the Bagó Group of Argentina, established in 2002 and publicly listed on the Pakistan Stock Exchange under psx:BFBIO. The company runs Pakistan's first biopharmaceutical production facility — located in Raiwind, Lahore, and designed to USFDA standards — which was expanded in FY 2024-25 with a new Line II featuring a high-speed pre-filled syringes line, a 42 square meter lyophilizer, and a combi filling line.

The company's commercial portfolio is concentrated in branded generics and proprietary in-licensed products across hepatology (Hepatitis A–E, hepatic encephalopathy, hepatorenal syndrome, hepatocellular carcinoma, portal hypertension), oncology (ovarian, colorectal, lung, breast, bladder, gastric, head and neck, prostate cancers; chemotherapy-induced neutropenia and CINV; fungal infections), cardiology (cardiac failure, angina), diabetes/obesity (Zeptide®, a US FDA-approved pre-filled syringe therapy launched in October 2025), and adjacent areas including chronic kidney disease, rheumatoid arthritis, and gastroenterology. Distribution is a physician-led, hospital-channel model with B2B contact infrastructure (customers@, exports@, bizdev@), international reach via the Bagó Group's 47+ country network, and a 98%-owned retail pharmacy partnership firm (Farmeshia/Formichea) for last-mile domestic reach.

The business is governed under Pakistani listed-company disclosure standards (Investor Corner, AGM voting, Free Float statements, IPO documents), supported by a dedicated pharmacovigilance and adverse-event reporting program, and is currently undergoing a leadership transition — COO Muhammad Farhan Rafique is scheduled to succeed Akhter Khalid Waheed as CEO effective January 1, 2026. Pricing is not publicly disclosed at the product level; revenue mechanics are based on branded pharmaceutical product sales across domestic and export channels.

Name

BF Biosciences

Legal name

BF Biosciences Limited

Website

https://bfbio.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

BF Biosciences Limited is a Pakistani biopharmaceutical joint venture between Ferozsons Laboratories and Argentina's Bagó Group, operating the country's first USFDA-standard biopharma facility in Lahore to manufacture and distribute branded generics and in-licensed therapies in hepatology, oncology, cardiology, and diabetes/obesity across domestic and export markets.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Branded Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industries

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Biopharmaceutical manufacturing
• Branded generic drugs
• Hepatology therapeutics
• Oncology pharmaceuticals
• Pre-filled syringes

Headquarters

HQ city

Raiwind

HQ country

Pakistan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Branded pharmaceutical product sales: Sale of branded generic and biopharmaceutical products (oncology, hepatology, cardiology, diabetes/obesity, fungal infections) to healthcare providers, hospitals, and patients in Pakistan and export markets. Includes the Bagó range of branded generics and proprietary in-licensed products.
2. New therapeutic product launches: Revenue from newly launched advanced therapeutics such as Zeptide (US FDA approved treatment for Type 2 Diabetes and Obesity) in pre-filled syringe format.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

BF Biosciences Limited manufactures and markets a portfolio of branded generic and biopharmaceutical drugs across hepatology, oncology, cardiology, diabetes/obesity, and other therapeutic areas at Pakistan's first USFDA-standard biopharmaceutical production facility in Lahore. Its commercial range covers hepatitis A-E, hepatic encephalopathy, hepatorenal syndrome, hepatocellular carcinoma, multiple cancers (ovarian, colorectal, lung, breast, bladder, gastric, head and neck, prostate), cardiovascular diseases, chronic kidney disease, rheumatoid arthritis, and fungal infections, with the most recent flagship product being Zeptide® (US FDA-approved Type 2 Diabetes and Obesity therapy in pre-filled syringe format).

Product overview

BF Biosciences Limited is a single, unified biopharmaceutical company — a joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina — built around one core production platform: Pakistan's first biopharmaceutical manufacturing facility in Lahore, designed to USFDA standards and recently expanded with 'Line II' (pre-filled syringes, 42 sqm lyophilizer, combi filling line). The company's commercial offering is a branded generics portfolio spanning hepatology, oncology, cardiology, and other therapeutic areas, with the most recent flagship launch being Zeptide® (US FDA-approved treatment for Type 2 Diabetes and Obesity, available in Pakistan in pre-filled syringe format since October 2025). Alongside the product portfolio, BF Biosciences operates supporting services including a Pharmacovigilance / Drug Safety reporting program for patients and physicians.

Differentiator

Problem solved

Functional benefit

Brands

• Zeptide®: Zeptide® is an advanced US FDA-approved treatment for Type 2 Diabetes and Obesity, available in a pre-filled syringe format, launched in Pakistan by BF Biosciences Limited in October 2025.

Products and services

• Zeptide® Zeptide® is a US FDA-approved treatment for Type 2 Diabetes and Obesity, launched in Pakistan by BF Biosciences Limited in October 2025 in a pre-filled syringe format. It is positioned as a globally validated therapy with emphasis on safety and ease of use for Pakistan's high-prevalence diabetes population.
• Therapeutic Portfolio (Hepatology, Oncology, Cardiology, and other disease areas)
• Pharmacovigilance / Drug Safety Reporting Service

Quantifiable outcome

• Achieved top 3 position in both Oncology and Hepatology segments in Pakistan within the first two years (2002 onward) of the Ferozsons–Bagó partnership.
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered flagship / core, minor / csr, core and major / regulatory.

• Ferozsons Laboratories Limitedflagship / coreStrategic or Co-development PartnerBF Biosciences Limited is a joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina, established in 2002. Ferozsons and Bagó entered into commercial partnership to launch the Bagó range of quality branded generics in oncology and hepatology in Pakistan. Within the first two years, together they achieved a leadership position, becoming one of the top 3 companies in both Oncology and Hepatology segments. Ferozsons also funds the establishment of TCF Khalid Waheed Campus in memory of the founding CEO.
• Bagó Group of Argentinaflagship / coreStrategic or Co-development PartnerBF Biosciences is a joint venture with the Bagó Group of Argentina, one of the largest holdings in Latin America focused on healthcare and quality of life. Bagó provides in-licensed products, manufacturing technology transfer, and access to its international network of more than 25 in-licence products and 47+ country presence. The Bagó Group bulk chemical and pharmaceutical products are internationally renowned for top quality. Listed as part of Bagó's pharmaceutical companies: Laboratorios BF Biosciences (Pakistan).
• LUMS (Lahore University of Management Sciences)minor / csrOthersBF Biosciences / Ferozsons annually supports the National Outreach Programme (NOP) Scholarships and the Young Writers Workshop at LUMS, providing need-based scholarships for NOP students at the Syed Babar Ali School of Science & Engineering and the Mushtaq Gurmani School of Humanities & Social Sciences.
• The Citizens Foundation (TCF)minor / csrOthersTogether with members of the Khalid Waheed family, the company funded the establishment of the TCF Khalid Waheed Campus at Kot Addu, Muzaffargarh, in memory of Mr. Khalid Waheed, founding CEO of Ferozsons. The company also annually supports TCF in promoting primary education through funding and sponsorships (e.g., Heer Ranjha theatre performance).
• Ali Institute of Education (AIE)minor / csrGTM or Marketing PartnerCollaboration with Ali Institute of Education for Hepatitis awareness and prevention campaign in schools across Bhakkar, Hafizabad, and Lahore, engaging more than 7,000 school children and over 200 teachers on Hepatitis prevention messaging.
• National College of Arts (NCA), Lahoreminor / csrStrategic or Co-development PartnerArt for Humanity collaboration: BF Biosciences Limited provides need-based scholarships for NCA students. In exchange, NCA includes an annual field elective in its curriculum where 3rd year students and NCA faculty work with the company to improve public sector hospital environments through art. First elective conducted in 2012 at the Oncology Ward of Mayo Hospital Lahore.
• University of Kelaniya, Sri Lankaminor / csrStrategic or Co-development PartnerArt for Humanity collaboration: Ferozsons Laboratories Limited and the University of Kelaniya (Department of Fine Arts) jointly run art interventions in clinical settings in Sri Lanka, with multiple medical institutes benefiting. Project was in its fourth year as referenced, with newer projects at the National Institute of Medical Health and St. Joseph's School for Deaf and Differently Abled.
• Lahore Literary Festival (LLF)minor / csrGTM or Marketing PartnerFerozsons Laboratories Limited is among the supporters of the annual Lahore Literary Festival; supported the 5th edition (February 2017), which featured prominent writers, historians, artists, and key opinion leaders in socio-political discussions.
• Mövenpick Hotels & Resorts (Karachi)minor / csrGTM or Marketing PartnerFerozsons Laboratories Limited supported Mövenpick Hotel Karachi's 'Kilo of Kindness' CSR campaign, contributing to the collection of school supplies for 'The Street School' run by two enthusiastic teenagers in Karachi.
• Farmeshia / Formichea (Pharmaceutical Partnership Firm)coreChannel Partner/ Reseller/ DistributorSubsidiary partnership firm under Partnership Act 1932, with 98% company share, engaged in retail pharmacy business to bring pharmaceutical products within reach of the public. Annual profit share (if any), if not withdrawn, is reinvested in the partnership capital account.
• US FDA (referenced approval authority)major / regulatoryOthersZeptide (launched in Pakistan) is approved by the US FDA. While not a commercial partnership, US FDA regulatory approval is a key relationship underpinning product credibility and market access.
• Muhammad Farhan Rafique (incoming CEO)coreOthersAppointed as new CEO of BF Biosciences Limited effective January 1, 2026, succeeding Akhter Khalid Waheed. Previously COO, Rafique contributed to the company's expansion, IPO, and digital projects.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Ferozsons Laboratories Limited: Pakistan-based branded generics manufacturer and 50% JV parent of BF Biosciences. Operates the same therapeutic areas (hepatology, oncology, cardiology) and shares distribution infrastructure, making it the most directly comparable peer and a benchmark for Pakistan pharma execution.
• The Searle Company Limited: Listed Pakistani pharma manufacturer with a branded generics and biosimilars portfolio spanning cardiology, gastroenterology, and oncology. Competes head-to-head with BF Biosciences in physician channels and offers a direct read on domestic pharma unit economics.
• Getz Pharma (Private) Limited: Pakistan's largest local pharma by volume with a branded generics portfolio across multiple therapeutic areas and WHO cGMP-compliant manufacturing. Directly comparable in business model, customer base (physicians/hospitals), and regulatory positioning.
• Hilton Pharma (Private) Limited: Pakistani branded generics manufacturer with a portfolio spanning anti-infectives, cardiology, and CNS. Competes with BF Biosciences for physician share-of-voice and formulary inclusion in tertiary hospitals.
• National Pharmaceuticals (Pvt.) Ltd. One of Pakistan's oldest local pharma manufacturers with broad branded-generics coverage. Comparable business model and customer base; useful for benchmarking pricing, distribution, and public-sector procurement dynamics.

Broad incumbents

• Bagó Group (Laboratorios Bagó): Argentine pharma holding and 50% JV parent of BF Biosciences. Operates across Latin America with branded generics, in-licensed products, and OTC — comparable in therapeutic portfolio (oncology, hepatology, cardiology) and manufacturing footprint.
• Abbott Laboratories Pakistan: Multinational pharma affiliate in Pakistan with broad branded generics and biologics portfolio. Overlaps with BF Biosciences in hepatology, cardiology, and oncology channels, representing the largest competitive incumbent.
• Sanofi Pakistan: Multinational pharma with established Pakistan operations across diabetes, cardiology, and specialty care. Competes with BF Biosciences' Zeptide (diabetes/obesity) and is a key benchmark for multinational entry dynamics.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-based branded generics manufacturer serving MENA with similar therapeutic breadth (anti-infectives, cardiology, diabetes). Comparable in scale and emerging-market branded-generics business model; relevant proxy for BF Biosciences' potential Middle East/Asia export expansion.

Others

• Pharmacia (BF Biosciences' retail partnership): 98%-owned retail pharmacy partnership firm that distributes BF Biosciences' products to end consumers. Functions as an integrated downstream channel rather than an external competitor, but illustrates the vertical integration model.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/ferozsonslabs

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BF Biosciences